U.S. Compounding Pharmacies Market Size By Pharmacy Type, By Sterility, By Product, By Application, By Compounding Type, By Therapeutic Area, Industry Analysis Report, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022

Description

List of Tables

The U.S. compounding pharmacies market is set to witness robust growth through 2030 owing to increasing acceptance of personalized medicines. In addition, easy availability of compounded drugs, along with prevalent drug shortage in the U.S., is also expected to spur market expansion over the forecast timeframe.

Notably, industry players have been adopting profitable strategies to improve their business presence, enhancing overall market dynamics. For instance, in March 2022, Medisca, a supplier of pharmaceutical equipment and ingredients, inked an agreement with SUANFARMA, a European distributor and manufacturer of pharmaceutical ingredients, for the global distribution and supply of Thyroid Powder, USP, for which it leveraged its partnership with Deebio, a pharmaceutical manufacturer.

The U.S. compounding pharmacies market has been bifurcated in terms of application, product, pharmacy type, sterility, compounding type, and therapeutic area. Based on application, the market has been segmented into adult, veterinary, geriatric, and pediatric. Owing to rising adoption rates of compounded medication by veterinary clinics, the veterinary sub-segment is set to depict a CAGR of more than 5.1% between 2022 and 2030.

On the basis of product, the U.S. compounding pharmacies market has been divided into topical, parenteral, nasal, otic, ophthalmic, rectal, and oral. The nasal sub-segment is foreseen to expand at a CAGR of about 5.5% over the forecast timeframe driven by increasing occurrences of ENT disorders that can be treated easily with nasal compounded medications. Additionally, the ease of usage of compounded nasal drops is likely to aid segmental growth.

With respect to pharmacy type, the market has been branched into 503A and 503B. The 503B sub-segment garnered a market share of over 56.5% in 2021 owing to a surge in drug shortages in the U.S., coupled with mounting preference for outsourcing facilities for manufacturing drugs that are in short supply.

By sterility, the U.S. compounding pharmacies market has been fragmented into non-sterile and sterile. In 2021, the non-sterile sub-segment was valued at more than $3.7 billion due to several benefits of non-sterile compounded medications, such as easy availability, self-administration, and personalized route of administration.

With regards to compounding type, the market has been segregated into unavailable pharmaceutical manufacturing (CUPM), pharmaceutical ingredient alteration (PIA), currently pharmaceutical dosage alteration (PDA), and others. The currently unavailable pharmaceutical manufacturing (CUPM) sub-segment held a market share of about 22.8% in 2021 on account of surging incidences of drug shortage across the U.S. In addition, compounded pharmacies play a vital role in curbing drug shortages, which is primed to supplement segmental development.

From the perspective of therapeutic area, the U.S. compounding pharmacies market has been categorized into nutritional supplements, dermatology, hormone replacement, pain management, specialty drugs, and others. In 2021, the specialty drugs sub-segment held around 9.6% market share supported by the ease of formulation of specialty drugs by compounding pharmacies, coupled with rising interest in personalized medicine to predict, diagnose, and treat diseases.

Product Code: 2961

Chapter 1 Methodology

1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 U.S. compounding pharmacies industry 360 degree synopsis, 2017 - 2030

Chapter 3 US Compounding Pharmacies Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Increasing geriatric population and improved longevity
  - 3.3.1.2 Growing acceptance of personalized medicines in U.S.
  - 3.3.1.3 Increasing drug shortage in the country
  - 3.3.1.4 Convenience of using compounded drugs
  - 3.3.1.5 Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women
- 3.3.2 Restraints
  - 3.3.2.1 Issues related to safety standards of compounded drugs
  - 3.3.2.2 Changing regulatory scenario
3.4 Growth potential analysis
- 3.4.1 By pharmacy type
- 3.4.2 By sterility
- 3.4.3 By product
- 3.4.4 By application
- 3.4.5 By compounding type
- 3.4.6 By therapeutic area
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.7 Reimbursement landscape
3.8 Porter's analysis
3.9 Competitive landscape, 2021
3.10 PESTEL analysis

Chapter 4 US Compounding Pharmacies Market, By Pharmacy Type

4.1 Key segment trends
4.2 503A
- 4.2.1 Market size, by 503A, 2017-2030 (USD Million)
4.3 503B
- 4.3.1 Market size, by 503B, 2017-2030 (USD Million)

Chapter 5 US Compounding Pharmacies Market, By Sterility

5.1 Key segment trends
5.2 Sterile
- 5.2.1 Market size, by sterile, 2017-2030 (USD Million)
5.3 Non-sterile
- 5.3.1 Market size, by non-sterile, 2017-2030 (USD Million)

Chapter 6 US Compounding Pharmacies Market, By Product

6.1 Key segment trends
6.2 Oral
- 6.2.1 Market size, by oral, 2017-2030 (USD Million)
- 6.2.2 Solid preparation
  - 6.2.2.1 Market size, by solid preparation, 2017-2030 (USD Million)
  - 6.2.2.2 Tablets
    - 6.2.2.2.1 Market size, by tablets, 2017 - 2030 (USD Million)
  - 6.2.2.3 Capsules
    - 6.2.2.3.1 Market size, by capsules, 2017 - 2030 (USD Million)
  - 6.2.2.4 Granules
    - 6.2.2.4.1 Market size, by granules, 2017 - 2030 (USD Million)
  - 6.2.2.5 Powder
    - 6.2.2.5.1 Market size, by powder, 2017 - 2030 (USD Million)
  - 6.2.2.6 Others
    - 6.2.2.6.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.3 Liquid preparation
  - 6.2.3.1 Market size, by liquid preparation, 2017-2030 (USD Million)
  - 6.2.3.2 Solutions
    - 6.2.3.2.1 Market size, by solutions, 2017 - 2030 (USD Million)
  - 6.2.3.3 Suspension
    - 6.2.3.3.1 Market size, by suspension, 2017 - 2030 (USD Million)
  - 6.2.3.4 Emulsion
    - 6.2.3.4.1 Market size, by emulsion, 2017 - 2030 (USD Million)
  - 6.2.3.5 Syrup
    - 6.2.3.5.1 Market size, by syrup, 2017 - 2030 (USD Million)
  - 6.2.3.6 Others
    - 6.2.3.6.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.4 Topical
  - 6.2.4.1 Market size, by topical, 2017-2030 (USD Million)
  - 6.2.4.2 Creams
    - 6.2.4.2.1 Market size, by creams, 2017 - 2030 (USD Million)
  - 6.2.4.3 Gels
    - 6.2.4.3.1 Market size, by gels, 2017 - 2030 (USD Million)
  - 6.2.4.4 Pastes
    - 6.2.4.4.1 Market size, by pastes, 2017 - 2030 (USD Million)
  - 6.2.4.5 Ointments
    - 6.2.4.5.1 Market size, by ointments, 2017 - 2030 (USD Million)
  - 6.2.4.6 Others
    - 6.2.4.6.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.5 Rectal
  - 6.2.5.1 Market size, by rectal, 2017-2030 (USD Million)
  - 6.2.5.2 Suppositories
    - 6.2.5.2.1 Market size, by suppositories, 2017 - 2030 (USD Million)
  - 6.2.5.3 Enemas
    - 6.2.5.3.1 Market size, by enemas, 2017 - 2030 (USD Million)
  - 6.2.5.4 Others
    - 6.2.5.4.1 Market size, by others, 2017 - 2030 (USD Million)
- 6.2.6 Parenteral
  - 6.2.6.1 Market size, by parenteral, 2017-2030 (USD Million)
  - 6.2.6.2 Small volume parenteral (SVP) solutions
    - 6.2.6.2.1 Market size, by small volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
  - 6.2.6.3 Large volume parenteral (LVP) solutions
    - 6.2.6.3.1 Market size, by large volume parenteral (SVP) solutions, 2017 - 2030 (USD Million)
- 6.2.7 Nasal
  - 6.2.7.1 Market size, by nasal, 2017-2030 (USD Million)
- 6.2.8 Ophthalmic
  - 6.2.8.1 Market size, by ophthalmic, 2017-2030 (USD Million)
- 6.2.9 Otic
  - 6.2.9.1 Market size, by otic, 2017-2030 (USD Million)

Chapter 7 US Compounding Pharmacies Market, By Application

7.1 Key segment trends
7.2 Pediatric
- 7.2.1 Market size, by pediatric, 2017-2030 (USD Million)
7.3 Adult
- 7.3.1 Market size, by adult, 2017-2030 (USD Million)
7.4 Geriatric
- 7.4.1 Market size, by geriatric, 2017-2030 (USD Million)
7.5 Veterinary
- 7.5.1 Market size, by veterinary, 2017-2030 (USD Million)

Chapter 8 US Compounding Pharmacies Market, By Compounding Type

8.1 Key segment trends
8.2 Pharmaceutical Ingredient Alteration (PIA)
- 8.2.1 Market size, by pharmaceutical ingredient alteration (PIA), 2017-2030 (USD Million)
8.3 Currently Unavailable Pharmaceutical Manufacturing (CUPM)
- 8.3.1 Market size, by currently unavailable pharmaceutical manufacturing (CUPM), 2017-2030 (USD Million)
8.4 Pharmaceutical Dosage Alteration (PDA)
- 8.4.1 Market size, by pharmaceutical dosage alteration (PIA), 2017-2030 (USD Million)
8.5 Others
- 8.5.1 Market size, by others, 2017-2030 (USD Million)

Chapter 9 US Compounding Pharmacies Market, By Therapeutic Area

9.1 Key segment trends
9.2 Hormone replacement
- 9.2.1 Market size, by hormone replacement, 2017-2030 (USD Million)
9.3 Pain management
- 9.3.1 Market size, by pain management, 2017-2030 (USD Million)
9.4 Dermatology
- 9.4.1 Market size, by dermatology, 2017-2030 (USD Million)
9.5 Specialty drugs
- 9.5.1 Market size, by specialty drugs, 2017-2030 (USD Million)
9.6 Nutritional supplements
- 9.6.1 Market size, by nutritional supplements, 2017-2030 (USD Million)
9.7 Others
- 9.7.1 Market size, by others, 2017-2030 (USD Million)

Chapter 10 Company Profiles

10.1 Strategy dashboard, 2021
10.2 Athenex Pharma Solutions (Athenex Inc.)
- 10.2.1 Business overview
- 10.2.2 Financial data
- 10.2.3 Product landscape
- 10.2.4 Strategic outlook
- 10.2.5 SWOT analysis
10.3 B Braun Melsungen AG
- 10.3.1 Business overview
- 10.3.2 Financial data
- 10.3.3 Product landscape
- 10.3.4 SWOT analysis
10.4 Clinigen Group PLC
- 10.4.1 Business overview
- 10.4.2 Financial data
- 10.4.3 Product landscape
- 10.4.4 Strategic outlook
- 10.4.5 SWOT analysis
10.5 Dougherty's Pharmacy, Inc.
- 10.5.1 Business overview
- 10.5.2 Financial data
- 10.5.3 Product landscape
- 10.5.4 SWOT analysis
10.6 Fagron
- 10.6.1 Business overview
- 10.6.2 Financial data
- 10.6.3 Product landscape
- 10.6.4 Strategic outlook
- 10.6.5 SWOT analysis
10.7 Fresenius Kabi
- 10.7.1 Business overview
- 10.7.2 Financial data
- 10.7.3 Product landscape
- 10.7.4 Strategic outlook
- 10.7.5 SWOT analysis
10.8 ImprimisRx (Harrow Health, Inc.)
- 10.8.1 Business overview
- 10.8.2 Financial data
- 10.8.3 Product landscape
- 10.8.4 Strategic outlook
- 10.8.5 SWOT analysis
10.9 Institutional Pharmacy Solutions
- 10.9.1 Business overview
- 10.9.2 Financial data
- 10.9.3 Product landscape
- 10.9.4 Strategic outlook
- 10.9.5 SWOT analysis
10.10 ITC Compounding Pharmacy
- 10.10.1 Business overview
- 10.10.2 Financial data
- 10.10.3 Product landscape
- 10.10.4 Strategic outlook
- 10.10.5 SWOT analysis
10.11 Lorraine's Pharmacy
- 10.11.1 Business overview
- 10.11.2 Financial data
- 10.11.3 Product landscape
- 10.11.4 Strategic outlook
- 10.11.5 SWOT analysis
10.12 McGuff Company Inc (McGuff Compounding Pharmacy Services)
- 10.12.1 Business overview
- 10.12.2 Financial data
- 10.12.3 Product landscape
- 10.12.4 Strategic outlook
- 10.12.5 SWOT analysis
10.13 Nephron Pharmaceuticals Corporation
- 10.13.1 Business overview
- 10.13.2 Financial data
- 10.13.3 Product landscape
- 10.13.4 Strategic outlook
- 10.13.5 SWOT analysis
10.14 Pencol Compounding Pharmacy
- 10.14.1 Business overview
- 10.14.2 Financial data
- 10.14.3 Product landscape
- 10.14.4 Strategic outlook
- 10.14.5 SWOT analysis
10.15 QuVa Pharma
- 10.15.1 Business overview
- 10.15.2 Financial data
- 10.15.3 Product landscape
- 10.15.4 Strategic outlook
- 10.15.5 SWOT analysis
10.16 Rx3 Compounding Pharmacy
- 10.16.1 Business overview
- 10.16.2 Financial data
- 10.16.3 Product landscape
- 10.16.4 Strategic outlook
- 10.16.5 SWOT analysis
10.17 Triangle Compounding Pharmacies
- 10.17.1 Business overview
- 10.17.2 Financial data
- 10.17.3 Product landscape
- 10.17.4 Strategic outlook
- 10.17.5 SWOT analysis
10.18 Wedgewood Village Pharmacy, Inc.
- 10.18.1 Business overview
- 10.18.2 Financial data
- 10.18.3 Product landscape
- 10.18.4 Strategic outlook
- 10.18.5 SWOT analysis